Diagnosis: Sézary syndrome
A 55-year-old male presents with a 6-month history of progressive erythroderma and generalized lymphadenopathy. Laboratory evaluation reveals circulating atypical lymphocytes, raising suspicion for a cutaneous T-cell lymphoma variant associated with severe skin involvement and systemic symptoms.
The patient is a 55-year-old male with a 6-month history of worsening erythroderma, pruritus, and notable generalized lymphadenopathy. On examination, the skin is diffusely red and scaly, with areas of crusting and excoriation. Lymph nodes in the cervical, axillary, and inguinal regions are markedly enlarged. The patient reports significant fatigue and weight loss over the past few months.Skin findings: Diffuse erythroderma with scaling and crusting.Lymphadenopathy: Palpable lymph nodes in multiple regions.Systemic symptoms: Fatigue, weight loss, and pruritus.Laboratory findings: Circulating atypical lymphocytes noted on peripheral blood smear.
The onset of symptoms began approximately 6 months ago with gradual skin changes and pruritus. The patient has no known triggers. He has a history of atopic dermatitis but has not undergone any significant treatments recently. There is no relevant family history of malignancies, and he denies any recent infections or travel. His social history is significant for a non-smoker and occasional alcohol use.Onset: Symptoms began 6 months ago.Prior treatments: No recent treatments; history of atopic dermatitis.Past medical history: No significant comorbidities.Family history: No known malignancies.Social history: Non-smoker and occasional alcohol use.
Acute / First-Line ManagementPhototherapy: Narrowband UVB or PUVA therapy can be initiated, with a typical regimen of 2-3 times weekly sessions.Systemic therapies: Consider methotrexate at a starting dose of 15-25 mg weekly, titrated based on tolerance and response.Corticosteroids: Systemic corticosteroids such as prednisone 0.5-1 mg/kg/day can be used for rapid control of severe symptoms.Workup and Diagnostic ConfirmationSkin biopsy: Essential for histopathological examination to identify atypical lymphocytes in the epidermis and dermis.Peripheral blood flow cytometry: To assess for T-cell clonality and confirm the diagnosis.Imaging studies: CT or PET scans may be indicated to evaluate lymphadenopathy and assess for systemic involvement.Long-Term ManagementMaintenance therapy: Long-term phototherapy or low-dose oral retinoids such as acitretin may be utilized.Targeted therapies: Consider brentuximab vedotin or mogamulizumab for refractory cases.Regular follow-up: Monitor for disease progression and treatment-related adverse effects.
Mycosis fungoides: The most common form of cutaneous T-cell lymphoma, characterized by patches, plaques, and tumors; typically presents with a more indolent course.Contact dermatitis: Can present with erythroderma; however, a clear exposure history or pattern of lesions is usually evident.Psoriasis: Presents with well-defined plaques, and the presence of nail changes can aid in differentiation.Drug eruption: Acute onset of erythroderma may suggest a drug-induced cause; review of medications is essential.Secondary syphilis: Can cause generalized rash and lymphadenopathy, but serologic testing will be positive.Exfoliative dermatitis: May present similarly but often has a more acute onset and can be due to underlying systemic conditions.Chronic eczema: Presents with widespread dermatitis and itching, but is often less extensive and has a different distribution.Other hematologic malignancies: Such as leukemias or lymphomas, may present with skin involvement and systemic symptoms, necessitating thorough evaluation.
High-Yield PearlsCirculating atypical lymphocytes: A hallmark of Sézary syndrome that differentiates it from other forms of cutaneous T-cell lymphoma.Erythroderma: The presence of widespread redness and scaling is critical for diagnosis; it can significantly impact quality of life.Staging: Accurate staging and classification are essential for guiding treatment options; the TNMB classification system is widely used.Systemic treatments: Methotrexate and phototherapy are first-line options; systemic steroids can provide rapid relief.Follow-up: Regular monitoring for disease progression and treatment side effects is crucial in long-term management.Early recognition and appropriate management of Sézary syndrome are pivotal to improving patient outcomes and quality of life.
Tags: Sézary syndrome, CTCL, erythroderma